对获得性广谱β-内酰胺酶对单独或联合使用β-内酰胺酶抑制剂阿维巴坦和替加环素的口服青霉素类/碳青霉烯类（替比培南、舒巴坦、法罗培南）敏感性的影响。
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in .
机构信息
Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg , Fribourg, Switzerland.
Division of Intensive Care Unit, University Hospitals of Geneva , Geneva, Switzerland.
出版信息
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0054723. doi: 10.1128/aac.00547-23. Epub 2023 Sep 5.
Abstract
The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant , including metallo-β-lactamase producers.
摘要
β-内酰胺酶对口服青霉素类/碳青霉烯类药物（替比培南、司帕培南和法罗培南）和其他碳青霉烯类分子的敏感性的影响，在 单独和与β-内酰胺酶抑制剂阿维巴坦或替加环素联合使用时进行了评估。替比培南和司帕培南与静脉用碳青霉烯类药物具有相似的活性谱，并显示出比头孢布烯-阿维巴坦更低的 MIC 值，对产生超广谱β-内酰胺酶或 AmpC 酶的 。与替加环素联合使用时，替比培南和司帕培南对几乎所有测试的重组 均表现出低 MIC 值，包括金属β-内酰胺酶产生菌。
相似文献
1
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in .
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0054723. doi: 10.1128/aac.00547-23. Epub 2023 Sep 5.
2
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
3
potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing .
Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0044023. doi: 10.1128/aac.00440-23. Epub 2023 Oct 6.
4
Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0055221. doi: 10.1128/AAC.00552-21.
5
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. doi: 10.1093/jac/dkaa053.
6
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16.
7
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0079022. doi: 10.1128/aac.00790-22. Epub 2022 Sep 1.
8
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Int J Antimicrob Agents. 2021 Nov;58(5):106440. doi: 10.1016/j.ijantimicag.2021.106440. Epub 2021 Sep 20.
9
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
J Antimicrob Chemother. 2021 Jan 1;76(1):160-170. doi: 10.1093/jac/dkaa391.
10
Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of strains producing broad-spectrum β-lactamases.
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0154823. doi: 10.1128/aac.01548-23. Epub 2024 Feb 28.
引用本文的文献
1
Pharmacokinetics/Pharmacodynamics-Based Repositioning of Cefmetazole and Flomoxef in Extended-Spectrum β-Lactamase-Producing Enterobacterales Treatment: An Injectable Carbapenem-Sparing and Outpatient Strategy.
Antibiotics (Basel). 2025 Jul 23;14(8):737. doi: 10.3390/antibiotics14080737.
2
Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of from outpatient centers and nursing homes across the United States (2022-2024).
Antimicrob Agents Chemother. 2025 May 7;69(5):e0186724. doi: 10.1128/aac.01867-24. Epub 2025 Apr 3.
3
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic strains.
Antimicrob Agents Chemother. 2025 May 7;69(5):e0169924. doi: 10.1128/aac.01699-24. Epub 2025 Apr 1.
4
The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-β-lactamase against tebipenem.
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0068724. doi: 10.1128/aac.00687-24. Epub 2024 Jul 18.
本文引用的文献
1
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
2
NDM-9 resistance to taniborbactam.
Lancet Infect Dis. 2023 Apr;23(4):401-402. doi: 10.1016/S1473-3099(23)00069-5. Epub 2023 Feb 13.
3
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
J Antimicrob Chemother. 2022 Dec 23;78(1):101-107. doi: 10.1093/jac/dkac360.
4
Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of from a 2018-2020 Global Surveillance Collection.
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0093422. doi: 10.1128/aac.00934-22. Epub 2022 Oct 26.
5
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.
Clin Infect Dis. 2023 Jan 6;76(1):66-77. doi: 10.1093/cid/ciac738.
6
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.
Clin Infect Dis. 2023 Jan 6;76(1):78-88. doi: 10.1093/cid/ciac704.
7
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.
8
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
N Engl J Med. 2022 Apr 7;386(14):1327-1338. doi: 10.1056/NEJMoa2105462.
9
Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability.
Bioorg Med Chem. 2022 May 15;62:116722. doi: 10.1016/j.bmc.2022.116722. Epub 2022 Mar 23.
10
Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.
Infect Dis Ther. 2021 Dec;10(4):1815-1835. doi: 10.1007/s40121-021-00509-4. Epub 2021 Aug 6.
Zotero 插件